Antigen-Heterologous Vaccination Regimen Triggers Alternate Antibody Targeting in SARS-CoV-2-DNA-Vaccinated Mice.

Publication date: Feb 20, 2024

An in-depth analysis of antibody epitopes following vaccination with different regimens provides important insight for developing future vaccine strategies. B-cell epitopes conserved across virus variants may be ideal targets for vaccine-induced antibodies and therapeutic drugs. However, challenges lie in identifying these key antigenic regions, and directing the immune system to target them. We previously evaluated the immunogenicity of two candidate DNA vaccines encoding the unmodified spike protein of either the SARS-CoV-2 Index strain or the Beta variant of concern (VOC). As a follow-on study, we characterized here the antibody binding profiles of three groups of mice immunized with either the DNA vaccine encoding the SARS-CoV-2 Index strain spike protein only, the Beta VOC spike protein only, or a combination of both as an antigen-heterologous prime-boost regimen. The latter induced an antibody response targeting overlapping regions that were observed for the individual vaccines but with additional high levels of antibody directed against epitopes in the SD2 region and the HR2 region. These heterologous-vaccinated animals displayed improved neutralization breadth. We believe that a broad-focused vaccine regimen increases neutralization breadth, and that the in-depth analysis of B-cell epitope targeting used in this study can be applied in future vaccine research.

Open Access PDF

Concepts Keywords
Dna DNA vaccine
Future epitope mapping
Mice microarray
Sd2 neutralizing antibodies
Vaccine SARS-CoV-2


Type Source Name
disease VO vaccination
disease VO vaccinated
disease VO vaccine
disease IDO cell
pathway REACTOME Immune System
disease VO immunized
disease VO DNA vaccine
disease MESH Infectious Diseases
disease VO prime boost regimen
disease VO Glycoprotein
disease MESH infection
disease VO effective
disease IDO host
drug DRUGBANK Coenzyme M
drug DRUGBANK Angiotensin II
disease IDO site
disease IDO intervention
disease VO frequency
disease VO efficiency
disease VO population
disease VO USA
drug DRUGBANK 5-amino-1 3 4-thiadiazole-2-thiol
drug DRUGBANK Phosphate ion
disease VO injection
disease IDO blood
disease VO dose
disease VO manufacturer
disease VO immunization
drug DRUGBANK Tromethamine
drug DRUGBANK Amino acids
drug DRUGBANK Aspartame
drug DRUGBANK Indoleacetic acid
disease MESH SD1
drug DRUGBANK Diethylstilbestrol
drug DRUGBANK Gold
disease IDO infectivity
disease IDO immune response
disease IDO facility
drug DRUGBANK Guanosine
drug DRUGBANK Dimercaprol
disease VO titer
disease MESH COVID 19
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH breakthrough infection
drug DRUGBANK Carboxyamidotriazole
disease VO Optaflu
disease VO vaccine epitope

Original Article

(Visited 1 times, 1 visits today)